

Michigan Medicine

Advanced Genitourinary Malignancies Symposium

Saturday, November 22, 2025
8:00 a.m. – 3:30 p.m.

The Ann Arbor Sheraton
3200 Boardwalk, Ann Arbor 48108

Free to attend, but registration is required.

Target Audience

This symposium is intended for physicians, physicians in training (residents/fellows), medical students, pharmacists, and advanced practice providers in the field of advanced genitourinary cancers.

Description with Expected Results

The Michigan Medicine Rogel Cancer Center is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The Mission of the Rogel Cancer Center is to reduce the burden of cancer and advance health equity through transdisciplinary collaboration in research, education, patient care and community outreach.

Expected Results – at the conclusion of this symposium participants will be able to:

- Utilize the current state-of-the-art updates in the diagnosis, risk stratification, and treatment of advanced (metastatic) genitourinary cancers including prostate, renal, bladder, and testis.
- Access information and enroll advanced genitourinary cancer patients in current state-of-the-art, groundbreaking clinical trials at Michigan Medicine.

To Register

<https://michmed.org/92YYb>



Faculty Planners

Sarah Yentz, MD
Zachery Reichert, MD, PhD

Financial Disclosure Information


Individuals in control of content have no relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation and Credit Designation

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Michigan Medical School designates this live activity for a maximum of 4.75 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For More Information

email Jennifer Fossum at jpfossum@umich.edu



Michigan Medicine Advanced Genitourinary Malignancies Symposium

Morning Sessions

Session 1 : Bladder Cancer

Moderator: **Sarah Yentz, MD**

- 8:35-8:55 **Immunotherapy for Localized Bladder Cancer: Universal Strategy or Tailored Approach?**
Irene Tsung, MD; Clinical Assistant Professor of Internal Medicine
- 9:00-9:20 **Risk Stratification in MIBC: The Emerging Role of ctDNA**
Phillip Palmbos, MD, PhD; Associate Professor of Internal Medicine
- 9:25-9:45 **From Targets to Toxicity: Clinical Nuance in ADC Therapy for Bladder Cancer**
Phillip Palmbos, MD, PhD; Associate Professor of Internal Medicine
- 9:45-10:00 **Q & A**

Session 2 : Kidney Cancer

Moderator: **Sarah Yentz, MD**

- 10:15-10:35 **Stereotactic Body Radiotherapy for Localized RCC: Emerging Evidence, Evolving Role**
William Jackson, MD; Associate Professor of Radiation Oncology
- 10:40-11:05 **Choosing Wisely: Patient Selection for Adjuvant IO in Kidney Cancer**
Irene Tsung, MD; Clinical Assistant Professor of Internal Medicine
- 11:10-11:30 **Metastatic RCC with Bulky Primary: Navigating the Balance Between Local and Systemic Therapy**
Sarah Yentz, MD; Clinical Associate Professor of Internal Medicine
Udit Singhal, MD; Clinical Assistant Professor of Urology
- 11:30-11:45 **Q & A**

Buffet Lunch and Exhibitor Room

Afternoon Sessions

Session 3 : Prostate I

Moderator: **Zachery Reichert, MD, PhD**

- 12:45-1:05 **Managing the 'In-Between': Localized Prostate Cancer with Nodal PSMA Avidity**
Zachery Reichert, MD, PhD; Associate Professor of Internal Medicine and Urology
Bob Dess, MD; Associate Professor of Radiation Oncology
- 1:05-1:15 **When to Scan and What to Use: Imaging the Biochemically Recurrent Prostate Cancer Patient**
Bob Dess, MD; Associate Professor of Radiation Oncology
- 1:15-1:25 **When to Radiate? Managing the Primary and Metastases in Low-Volume Metastatic Castrate Sensitive Prostate Cancer**
William Jackson, MD; Associate Professor of Radiation Oncology
- 1:25-1:35 **Tailoring Systemic Treatment in Low-Volume mCSPC: How Long and What to Choose?**
Phoebe Tsao, MD; Clinical Assistant Professor of Internal Medicine
- 1:35-1:45 **To PET or not? Deciding the Best Imaging for Metastatic Prostate Cancer**
Phoebe Tsao, MD; Clinical Assistant Professor of Internal Medicine
- 1:45-2:00 **Q & A**

Session 4 : Prostate II

Moderator: **Zachery Reichert, MD, PhD**

- 2:15-2:30 **Pluvicto and Docetaxel in Metastatic Castrate Resistant Prostate Cancer: Making the Right Choice for Your Patient**
Sarah Yentz, MD; Clinical Associate Professor of Internal Medicine
Sean Miller, MD; Clinical Assistant Professor of Radiation Oncology and Nuclear Medicine
- 2:30-2:45 **Beyond Symptom Control: The Evolving Role of Radiation in Metastatic Castrate Resistant Prostate Cancer**
Sean Miller, MD; Clinical Assistant Professor of Radiation Oncology and Nuclear Medicine
- 2:45-3:00 **Germline Testing in Prostate Cancer: What the Oncologist Needs to Know**
Michelle Jacobs, MS, CGC; Genetic Counselor
- 3:00-3:15 **Next Generation Sequencing in Metastatic Prostate Cancer: When, Who, and Why**
Zachery Reichert, MD, PhD; Associate Professor of Internal Medicine and Urology
- 3:15-3:30 **Q & A**



ROGEL CANCER CENTER
UNIVERSITY OF MICHIGAN HEALTH

Free to attend, but
registration is required.

In partnership with:

